How to Invest in Eli Lilly and Company (LLY)

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Eli Lilly and Company's investor relations page or your broker.

• Revenue (TTM): ~$45 to 55 billion and growing fast (verify)
• Operating margin: ~30%+ (verify)
• Gross margin: ~80% (typical for branded pharma)
• P/E (TTM): ~40x to 60x (premium; verify)
• Dividend yield: ~0.6% to 0.8% (verify)
• Key franchise: Tirzepatide (Mounjaro + Zepbound) driving incretin growth
• R&D spending: Large; heavy reinvestment in pipeline and capacity
• Market cap: Among the most valuable healthcare companies (multi-hundred-billion to trillion range; verify)

Eli Lilly trades at a premium pharma multiple that prices in continued rapid growth from the obesity and diabetes franchise plus pipeline optionality. The valuation debate centers on how large, durable, and profitable the incretin market proves to be and how competition (chiefly Novo Nordisk and emerging oral incretins) shapes pricing and share. Figures are approximate and should be verified against the latest filings before drawing conclusions.

If you want LLY exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses LLY naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that show up alongside LLY in the same themes. Worth a look if you're thinking about diversification within a single thesis rather than concentration on one ticker.

There are three common ways to get LLY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (VUG, SCHG, MGK), which spreads the position across many companies. Or build it into a focused thematic basket, so LLY sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where LLY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Eli Lilly (LLY) is a large-cap pharma whose growth is currently powered by the GLP-1 obesity and diabetes franchise, supported by a diversified pipeline. In a portfolio it behaves as a premium-valued healthcare growth holding rather than a defensive dividend stock, with the durability and competitive dynamics of the incretin market as the central debate.